Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT3FLT4KDRKITPDGFRAPDGFRBRET
The experimentally established mechanism targets of Sunitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 16/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 7/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 3/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 2/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 13/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 12/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 5/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 2/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 2/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 2/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sunitinib SCHEMBL25343935 | 1.00 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL20805212 | 1.00 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL30314241 | 1.00 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL8082 | 1.00 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL25343938 | 1.00 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL2296353 | 0.99 | KDR (0.98) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL23668540 | 0.99 | KDR (0.98) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL28454734 | 0.99 | KDR (0.98) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL2716609 | 0.99 | KDR (0.98) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL1780287 | 0.98 | KDR (0.97) | KDRPRKAA1PRKAA2PDGFRBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 90038 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144866-A1 | METHODS, DEVICES, AND SYSTEMS FOR PREDICTING TREATMENT RESPONSIVENESS OF CLEAR CELL RENAL CELL CARCINOMA PATIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144750-A1 | Dosing Regimens for Treatment of Glioblastoma | SIGNPATH PHARMA INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3836899-B1 | CHEMOTHERAPEUTIC PHARMACEUTICAL SUSPENSION FOR ORAL DOSAGE | ONCOSOL LTD (GB) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075735-A | Therapeutic combinations comprising anti-FOLR 1 immunoconjugates | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| CN-116162546-B | Drug screening tumor organoid chip and drug screening method | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122074048-A | Methods of treating cancer | 诺华股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| US-20260137638-A1 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TYARDI OPERATING CO INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2006079644-A1 | INDOLOPYRIDINES, BENZOFURANOPYRIDINES AND BENZOTHIENOPYRIDINES | NYCOMED GMBH (DE) | 2006-08-03 | — | — | WO | claimed |
| WO-2006079645-A1 | NOVEL INDOLOPYRIDINES , BENZOFURANOPYRIDINES AND BENZOTHIENOPYRIDINES | NYCOMED GMBH (DE) | 2006-08-03 | — | — | WO | claimed |
| WO-2006075012-A2 | PYRROLODIHYDROISOQUINOLINES AS ANTIPROLIFERATIVE AGENTS | NYCOMED GMBH (DE) | 2006-07-20 | — | — | WO | claimed |
| WO-2006027346-A2 | NOVEL PYRAZOLOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | claimed |
| US-20050276812-A1 | maytansinoid drug moieties covalently linked by a linker to an antibody which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors; cancer | GENENTECH, INC. (US) | 2005-12-15 | — | — | US | claimed |
| WO-2005117986-A2 | ANTIBODY DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| JP-2005503386-A | — | — | 2005-02-03 | — | — | JP | claimed |
| EP-1419151-A1 | CHRYSTALS INCLUDING A MALIC ACID SALT OF N-[2-(DIETHYLAMINO)ETHYL]-5-[(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOLE-3-YLIDENE)METHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE, PROCESSES FOR ITS PREPARATION AND COMPOSITIONS THEREOF | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-19 | — | — | EP | claimed |
| US-20030069298-A1 | Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| WO-2003016305-A1 | CRYSTALS INCLUDING A MALIC ACID SALT OF N-[2-(DIETHYLAMINO) ETHYL]-5-[(5-FLUORO-2-OXO-3H-INDOLE-3-YLIDENE) METHYL]-2, 4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE, PROCESSES FOR ITS PREPARATION AND COMPOSITIONS THEREOF | PHARMACIA & UPJOHN COMPANY (US) | 2003-02-27 | — | — | WO | claimed |